Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw.
Platelet-rich plasma is a concentrate of growth factors and osteoconductive proteins, which can play a major role in bone biology by accelerating and enhancing bone repair and regeneration. This paper describes the results of using platelet-rich plasma in the management of bisphosphonate-associated necrosis of the jaw. Eight patients with a diagnosis of bisphosphonate-associated necrosis of the jaw were surgically treated for debridement and removal of necrotic bone, followed by application of autologous platelet concentrate enriched with growth factors and primary suture of the wound. Patients underwent periodic clinical and radiological follow-up examinations. All patients showed clinical improvement and oral lesions resolved 2-4 weeks after treatment. After an average 14-month follow up period, patients remained asymptomatic. Although not conclusive, the combination of necrotic-bone curettage and platelet-rich-plasma to treat refractory osteonecrosis of the jaw yielded promising results.
Hospital Universitario Insular de las Palmas de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Spain.
S
S
Bocanegra-Pérez
M
M
Vicente-Barrero
M
M
Knezevic
J M
JM
Castellano-Navarro
E
E
Rodríguez-Bocanegra
J
J
Rodríguez-Millares
D
D
Pérez-Plasencia
A
A
Ramos-Macías
D000368:Aged; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D053657:Platelet-Rich Plasma